• Je něco špatně v tomto záznamu ?

Relation Between Clinical Best Practices and 6-Month Outcomes After Transcatheter Aortic Valve Implantation With CoreValve (from the ADVANCE II Study)

JM. Sinning, AS. Petronio, N. Van Mieghem, G. Zucchelli, G. Nickenig, R. Bekeredjian, J. Bosmans, F. Bedogni, M. Branny, K. Stangl, J. Kovac, A. Nordell, M. Schiltgen, N. Piazza, P. de Jaegere,

. 2017 ; 119 (1) : 84-90. [pub] 20160930

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023583
E-zdroje Online Plný text

NLK ProQuest Central od 2012-08-15 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2012-08-15 do Před 2 měsíci
Health & Medicine (ProQuest) od 2012-08-15 do Před 2 měsíci

Odkazy

PubMed 27776799
DOI 10.1016/j.amjcard.2016.09.016
Knihovny.cz E-zdroje

Best practices for transcatheter aortic valve implantation with CoreValve include patient screening and valve size selection using multislice computed tomography, adherence to manufacturer recommendations for oversizing, control of implant depth to 6 mm or less, and management of conduction disturbances according to international guidelines. The ADVANCE II study implemented these strategies and demonstrated their relation to clinical outcomes. From October 2011 to April 2013, 200 patients with severe aortic stenosis were enrolled, and 194 were implanted. All imaging and electrocardiographic data were analyzed by an independent core laboratory, and adverse events were adjudicated to valve academic research consortium-2 definitions. The mean age was 80.2 ± 6.7 years and the mean Society of Thoracic Surgeons Predicted Risk of Mortality was 7.2 ± 6.8% for the enrolled patients. At 6 months, all-cause mortality was 9.2%, stroke was 2.6%, and permanent pacemaker implantation was 19.2% for class I and II indications. In patients with implant depth ≤6 mm, both mortality and permanent pacemaker implantation were lower than in patients with depth >6 mm (2.5% vs 14.5%, p <0.01 and 18.1% vs 31.7%, p = 0.03, respectively). The rate of moderate and severe paravalvular leak was 9.8% at 7 days after transcatheter aortic valve implantation, decreasing to 4.3% at 6 months (p = 0.02). Valves were significantly more oversized in patients with mild or less paravalvular leak at day 7 compared with those with moderate or severe (15.8 ± 8.0% vs 11.8 ± 4.9%, p = 0.01). In conclusion, findings from the ADVANCE II study reinforce that adherence to best clinical practices improves patient outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023583
003      
CZ-PrNML
005      
20200505145015.0
007      
ta
008      
170720s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.amjcard.2016.09.016 $2 doi
035    __
$a (PubMed)27776799
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sinning, Jan-Malte $u Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Bonn, Germany. Electronic address: jan-malte.sinning@ukb.uni-bonn.de.
245    10
$a Relation Between Clinical Best Practices and 6-Month Outcomes After Transcatheter Aortic Valve Implantation With CoreValve (from the ADVANCE II Study) / $c JM. Sinning, AS. Petronio, N. Van Mieghem, G. Zucchelli, G. Nickenig, R. Bekeredjian, J. Bosmans, F. Bedogni, M. Branny, K. Stangl, J. Kovac, A. Nordell, M. Schiltgen, N. Piazza, P. de Jaegere,
520    9_
$a Best practices for transcatheter aortic valve implantation with CoreValve include patient screening and valve size selection using multislice computed tomography, adherence to manufacturer recommendations for oversizing, control of implant depth to 6 mm or less, and management of conduction disturbances according to international guidelines. The ADVANCE II study implemented these strategies and demonstrated their relation to clinical outcomes. From October 2011 to April 2013, 200 patients with severe aortic stenosis were enrolled, and 194 were implanted. All imaging and electrocardiographic data were analyzed by an independent core laboratory, and adverse events were adjudicated to valve academic research consortium-2 definitions. The mean age was 80.2 ± 6.7 years and the mean Society of Thoracic Surgeons Predicted Risk of Mortality was 7.2 ± 6.8% for the enrolled patients. At 6 months, all-cause mortality was 9.2%, stroke was 2.6%, and permanent pacemaker implantation was 19.2% for class I and II indications. In patients with implant depth ≤6 mm, both mortality and permanent pacemaker implantation were lower than in patients with depth >6 mm (2.5% vs 14.5%, p <0.01 and 18.1% vs 31.7%, p = 0.03, respectively). The rate of moderate and severe paravalvular leak was 9.8% at 7 days after transcatheter aortic valve implantation, decreasing to 4.3% at 6 months (p = 0.02). Valves were significantly more oversized in patients with mild or less paravalvular leak at day 7 compared with those with moderate or severe (15.8 ± 8.0% vs 11.8 ± 4.9%, p = 0.01). In conclusion, findings from the ADVANCE II study reinforce that adherence to best clinical practices improves patient outcomes.
650    _2
$a senioři $7 D000368
650    _2
$a aortální stenóza $x diagnostické zobrazování $x chirurgie $7 D001024
650    12
$a bioprotézy $7 D001705
650    _2
$a Evropa $x epidemiologie $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    12
$a srdeční chlopně umělé $7 D006350
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a pooperační komplikace $x epidemiologie $7 D011183
650    _2
$a prospektivní studie $7 D011446
650    _2
$a transkatetrální implantace aortální chlopně $x přístrojové vybavení $7 D065467
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Petronio, Anna Sonia $u Cardiothoracic and Vascular Department, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
700    1_
$a Van Mieghem, Nicolas $u Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
700    1_
$a Zucchelli, Giulio $u Cardiothoracic and Vascular Department, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
700    1_
$a Nickenig, Georg $u Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Bonn, Germany.
700    1_
$a Bekeredjian, Raffi $u Department of Cardiology, Universitätsklinikum Heidelberg, Heidelberg, Germany.
700    1_
$a Bosmans, Johan $u Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium.
700    1_
$a Bedogni, Francesco $u Department of Cardiology, Istituto Clinico S. Ambrogio, Milan, Italy.
700    1_
$a Branny, Marian $u Department of Cardiology, Cardiocenter Hospital Podlesi, Trinec, Czech Republic.
700    1_
$a Stangl, Karl $7 xx0247475 $u Department of Cardiology and Angiology, Charite, Campus Mitte-Kardiologie, Berlin, Germany.
700    1_
$a Kovac, Jan $u Department of Cardiology, Glenfield Hospital, Leicester, United Kingdom.
700    1_
$a Nordell, Anna $u Department of Biostatistics, North American Sciences Associates, Inc., Minneapolis, Minnesota.
700    1_
$a Schiltgen, Molly $u Department of Heart Valve Therapies, Medtronic, Minneapolis, Minnesota.
700    1_
$a Piazza, Nicolo $u Department of Interventional Cardiology, McGill University Health Centre, Montreal, Quebec, Canada.
700    1_
$a de Jaegere, Peter $u Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
773    0_
$w MED00000236 $t The American journal of cardiology $x 1879-1913 $g Roč. 119, č. 1 (2017), s. 84-90
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27776799 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20200505145013 $b ABA008
999    __
$a ok $b bmc $g 1239264 $s 984496
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 119 $c 1 $d 84-90 $e 20160930 $i 1879-1913 $m The American journal of cardiology $n Am J Cardiol $x MED00000236
LZP    __
$a Pubmed-20170720
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace